Panacea Life Sciences Holdings Inc. (OTCMKTS:PLSH) Launches of CBDA Oil Drops as Potential Alternative Treatment for Long COVID
Panacea Life Sciences Holdings Inc. (OTCMKTS:PLSH) is a key player in producing legal, industrial hemp cannabinoid products for consumers and pets. It provides non-habit-forming health and wellness products as an alternative to expensive pharmaceuticals and synthetic product offerings. The product line includes softgels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals.
Market Stats
On Thursday, PLSH stock moved up 28% to at $0.4468 with more than11K shares, compared to its average volume of 3.4K share. The stock moved within a range of $0.1001 – 0.4499 after opening trading at $0.4499.
Panacea Life Sciences Announces Launch of CBDA Oil Drops as Potential Complementary Treatment for Long COVID
Panacea Life Sciences Holdings, Inc., announced on July 14, 2002 about adding CBDA Oil Drops, as a preventative agent against SARS-CoV-2 as well as the effects of Long COVID.
There are generally three types of long COVID: Excessive fatigue and shortness of breath, Heart rate spiking erratically, Brain fog.
Back in January 2022, the results of a study led by Oregon State University researcher Richard van Breemen, published in the Journal of Natural Products, stated that CBDA and CBGA can bind to the SARS-CoV-2 spike protein, and effectively the block virus’s ability to infect people. Of course, more research is required to make definitive claims, but CBD and CBDA may provide effective prevention and treatment of SARS-CoV-2, as a compliment to vaccines. Panacea’s CBDA Oil Drops tincture contains 50mg of CBDA per serving, along with immunity boosting Zinc and Vitamin D, remains one of few products of its kind to be available on the market.
Panacea’s Chief Science Officer, James Baumgartner, Ph.D., says that Panacea’s CBDA Oil Drops not only contain a significant amount of both cannabinoids, but even have extra immunity-building ingredients. The goal is to offer customers a product that naturally supports the body’s immune system. As a leading cannabinoid research company, it is their intention to conduct further research and studies that can positively impact the general and medical communities.
Lead Scientist, Melissa Reynolds, Ph.D. at the Colorado State University (CSU), along with her team of scientists at their Cannabinoid Research Center, and Panacea, are eager to work on this research. She says that the Panacea research center at CSU is well-equipped to further the research on this promising news and expand it to additional human clinical studies. There are over 115 cannabinoids in the hemp plant, and it is just scratching surface of what this natural plant can offer.
Panacea also attended the White Label World Expo in Las Vegas at the Convention Center from May 25-26, 2022, to showcase its broad capabilities live. It highlighted the newly acquired, proprietary vegan softgel capabilities as well as the launch of a new pet treat line. With specialties in softgel manufacturing, Panacea has the ability to produce 1.5M softgels per day and can also produce 10,000 liquid fills per day. The company provides full-range services from R&D and custom formulation to manufacturing and fulfillment from its 51,000 square foot facility located in Golden, Colorado.
Key Quote
According to Panacea’s Chief Science Officer, James Baumgartner, Ph.D., “Panacea’s CBDA Oil Drops not only contain a significant amount of both cannabinoids, but also have additional immunity-building ingredients to give our customers a product that naturally supports the body’s immune system. As a leading cannabinoid research company, our goal is to conduct further research and studies that can positively impact the general and medical communities.”
Traders Corner
PLSH stock is trading above the 20-Day and 50-Day Moving averages of $0.33 and $0.36 respectively. However, the stock is trading below the 200-Day moving average of $0.7850.
